Mark Cuban’s Cost Plus Drugs Offers New SGLT-2 Medication for Type 2 Diabetes


On Thursday, July 13, 2023, Mark Cuban’s Cost Plus Drug Company announced it will offer a 30-day supply of the newest SGLT-2 inhibitor on the market, Brenzavvy, for treating type 2 diabetes. A 30-day supply will cost $47.85 plus shipping. 

Cost Plus Drugs has no membership fees, and insurance is not required to fill a prescription for Brenzavvy at this price. 

SGLT-2s are also known as sodium-glucose cotransporters or gliflozins. This group of oral medications for managing type 2 diabetes is relatively new, as canagliflozin (Invokana), another SGLT-2 medication, was first approved in 2013. SGLT-2s help treat diabetes by reducing renal glucose reabsorption and increasing its urinary elimination, decreasing blood glucose concentrations. 

These medications prevent your kidneys from reabsorbing glucose concentrations into your bloodstream and help your body eliminate the excess through urine.

According to the Endocrinology Network, SGLT-2s lower blood glucose levels in two ways:

  • Reducing the amount of glucose the kidneys absorb to excrete through urine.
  • Reducing the amount of glucose in the bloodstream.

Cost Plus Drugs CEO and co-founder Dr. Alex Oshmyanksy shared that the company prioritizes products for people with diabetes like SGLT-2s. SGLT-2s are clinically shown to have meaningful benefits for people with type 2 diabetes, including reducing the risk of other comorbid conditions

“Unfortunately, Americans with diabetes have suffered from artificially inflated drug and supply prices for far too long,” Dr. Oshmyansky stated. “As a diabetic myself, I’ve experienced this issue first-hand, so adding more products for people with diabetes at reasonable prices is a top priority for us.”

With Cost Plus Drugs offering medications like Brenzavvy and Invokana at more affordable prices, access to SGLT-2 medicines can improve and positively impact over 30 million Americans living with type 2 diabetes today.  

WRITTEN BY Beyond Type 2 Editorial Team, POSTED 07/13/23, UPDATED 07/13/23

This piece was authored collaboratively by the Beyond Type 2 Editorial Team.